Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a Phase-3, randomized, placebo-controlled trial

被引：0

作者：

Elewski, B. E. ^{[1
]}

Rich, P. A. ^{[2
]}

Okun, M. M. ^{[3
]}

Papp, K. ^{[4
]}

Baker, C. S. ^{[5
,6
]}

Crowley, J. J. ^{[7
]}

Guillet, G. ^{[8
]}

Gu, Y. ^{[9
]}

Geng, Z. ^{[9
]}

Sundaram, M. ^{[10
]}

Williams, D. A. ^{[3
]}

机构：

[1] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA

[2] Oregon Hlth & Sci Univ Hosp, Portland, OR USA

[3] AbbVie, Dermatol, N Chicago, IL USA

[4] K Papp Clin Res & Prob Med Res, Waterloo, ON, Canada

[5] Skin & Canc Fdn Inc, Carlton, Vic, Australia

[6] Prob Med Res, Carlton, Vic, Australia

[7] Bakersfield Dermatol, Bakersfield, CA USA

[8] Hop La Miletrie, Serv Dermatol, Poitiers, France

[9] AbbVie, Stat, N Chicago, IL USA

[10] AbbVie, Hlth Econ Outcomes Res, N Chicago, IL USA

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷

关键词：

adalimumab; fingernail psoriasis; Phase; 3;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P131

引用

页码：65 / 65

页数：1

共 50 条

[1] Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial
Elewski, Boni E.
Okun, Martin M.
Papp, Kim
Baker, Christopher S.
Crowley, Jeffrey J.
Guillet, Gerard
Sundaram, Murali
Poulin, Yves
Gu, Yihua
Geng, Ziqian
Williams, David A.
Rich, Phoebe A.
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (01) : 90 - +
[2] Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial
Elewski, B. E.
Baker, C. S.
Crowley, J. J.
Poulin, Y.
Okun, M. M.
Calimlim, B.
Geng, Z.
Servin, O. Reyes
Rich, P. A.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (11) : 2168 - 2178
[3] PRIMARY EFFICACY AND SAFETY OF ADALIMUMAB IN NAIL PSORIASIS FROM THE FIRST 26 WEEKS OF A PHASE-3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH SUBANALYSIS IN PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS
Elewski, B. E.
Rich, P. A.
Behrens, F.
Guillet, G.
Geng, Z.
Servin, O. Reyes
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1319 - 1320
[4] PRIMARY EFFICACY AND SAFETY OF ADALIMUMAB IN NAIL PSORIASIS FROM THE FIRST 26 WEEKS OF A PHASE-3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH SUBANALYSIS IN PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS
Elewski, Boni E.
Rich, Pheobe A.
Behrens, Frank
Guillet, Gerard
Geng, Ziqian
Servin, Ofelia Reyes
[J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 26 - 27
[5] Efficacy of adalimumab in nail psoriasis by baseline subgroups, and overall safety from first 26 weeks of a phase 3, randomized, placebo-controlled trial
Rich, Phoebe A.
Baker, Christopher S.
Valenzuela, Fernando
Rey, Maria P.
Geng, Ziqian
Gu, Yihua
Servin, Ofelia Reyes
Poulin, Yves
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB200 - AB200
[6] Primary efficacy and safety of adalimumab in nail psoriasis from the first 26weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis
Elewski, Boni E.
Rich, Phoebe A.
Behrens, Frank
Guillet, Gerard
Geng, Ziqian
Servin, Ofelia Reyes
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB204 - AB204
[7] Adalimumab for nail psoriasis: Efficacy and safety from the open-label extension of a phase-3, randomized, placebo-controlled trial
Gottlieb, Alice B.
Elewski, Boni E.
Okun, Martin M.
Bagel, Jerry
Poulin, Yves
Gu, Yihua
Williams, David A.
Valdecantos, Wendell C.
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB33 - AB33
[8] Efficacy of adalimumab in nail psoriasis by history of psoriatic arthritis and overall safety from final, open-label 26 weeks of a phase 3, randomized, placebo-controlled trial
Elewski, Boni E.
Armstrong, April W.
Coates, Laura C.
Rubel, Diana
Rashid, Javed
Geng, Ziqian
Gu, Yihua
Servin, Ofelia Reyes
Behrens, Frank
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB201 - AB201
[9] Long-term safety and efficacy of adalimumab from the phase 3 randomized placebo-controlled trial in patients with nail and skin psoriasis
Crowley, Jeff
Gisondi, Paolo
Geng, Ziqian
Servin, Ofelia Reyes
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB181 - AB181
[10] LONG-TERM SAFETY AND EFFICACY OF ADALIMUMAB FROM THE PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH NAIL AND SKIN PSORIASIS
Crowley, Jeff
Gisondi, Paolo
Geng, Ziqian
Servin, Ofelia Reyes
[J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 25 - 25

← 1 2 3 4 5 →